Vivos Therapeutics, Inc. (VVOS) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	10-K	10-K	10-K	S-1/A
Revenues [+]	16.9	13.1	11.4	3.8
Products				1.8
Services				1.9
Net interest income	0.1	0.1
Revenue growth	29.2%	14.7%	200.4%
Cost of goods sold	0.1	0.1	2.7	1.1
Gross profit	16.8	13.0	8.7	2.7
Gross margin	99.4%	99.2%	76.0%	71.5%
Selling, general and administrative [+]	31.3	18.4	18.5	10.4
Sales and marketing	5.6	2.3	2.3	1.2
General and administrative	25.8	16.1	16.2	9.3
Other operating expenses	4.2	2.6
EBITDA [+]	-18.7	-8.0	-9.8	-7.7
EBITDA growth	134.5%	-18.7%	27.2%
EBITDA margin	-111.0%	-61.2%	-86.2%	-203.7%
Depreciation	0.4	0.3	0.3	0.6
EBITA	-19.2	-8.3	-10.2	-8.3
EBITA margin	-113.5%	-63.6%	-89.1%	-219.8%
Amortization of intangibles	0.3	0.4	0.4
EBIT [+]	-19.5	-8.7	-10.6	-8.3
EBIT growth	123.6%	-17.7%	26.9%
EBIT margin	-115.3%	-66.7%	-92.8%	-219.8%
Non-recurring items [+]	0.9	3.3
Asset impairment	0.9
Legal settlement		3.3
Interest expense, net [+]	0.0	0.1	0.1	0.1
Interest expense	0.0	0.1	0.1	0.1
Interest income			0.0
Other income (expense), net [+]	0.1	0.1	-0.1
Gain (loss) on sale of business			-0.1
Other	0.0
Pre-tax income	-20.3	-12.1	-10.8	-8.4
Income taxes	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%
Net income	-20.3	-18.0	-11.8	-9.4
Net margin	-120.2%	-137.7%	-103.2%	-248.9%

Basic EPS [+]	($0.96)	($1.40)	($0.95)	($0.82)
Growth	-31.6%	46.6%	16.6%
Diluted EPS [+]	($0.96)	($1.40)	($0.95)	($0.82)
Growth	-31.6%	46.6%	16.6%

Shares outstanding (basic) [+]	21.2	12.9	12.3	11.5
Growth	65.0%	4.4%	6.8%
Shares outstanding (diluted) [+]	21.2	12.9	12.3	11.5
Growth	65.0%	4.4%	6.8%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.